Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab and Irinotecan Liposome in Relapsed SCLC
NCT06478043Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in small cell lung cancer (SCLC), sponsored by Zhejiang Cancer Hospital. Started Oct 2024; status: completed.
02
Drugs
ivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06478043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478043.